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ABSTRACT
Aneuploidy is a widely studied prognostic marker in endometrial cancer (EC), 
however, not implemented in clinical decision-making. It lacks validation in large 
prospective patient cohorts adjusted for currently standard applied prognostic 
markers, including estrogen/progesterone receptor status (ER/PR). Also, little is 
known about aneuploidy-related transcriptional alterations, relevant for understanding 
its role in EC biology, and as therapeutic target.
We included 825 EC patients with available ploidy status and comprehensive 
clinicopathologic characterization to analyze ploidy as a prognostic marker. For 
144 patients, gene expression data were available to explore aneuploidy-related 
transcriptional alterations.
Aneuploidy was associated with high age, FIGO stage and grade, non-
endometrioid histology, ER/PR negativity, and poor survival (p-values<0.001). In 
patients with ER/PR negative tumors, aneuploidy independently predicted poor 
survival (p=0.03), lymph node metastasis (p=0.007) and recurrence (p=0.002). A 
prognostic ‘aneuploidy signature’, linked to low expression of chromosome 15q genes, 
was identified and validated in TCGA data.
In conclusion, aneuploidy adds prognostic information in ER/PR negative EC, 
identifying high-risk patients that could benefit from more aggressive therapies. The 
‘aneuploidy signature’ equally identifies these aggressive tumors and suggests a link 
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between aneuploidy and low expression of 15q genes. Integrated analyses point at 
various dysregulated pathways in aneuploid EC, underlining a complex biology.
INTRODUCTION
Aneuploidy, defined as an aberrant number of 
chromosomes, is a commonly observed feature in human 
cancers [1], including endometrial cancer (EC) [2]. 
Aneuploidy is often evaluated in tumors as an indirect 
measure of chromosomal instability, and used as an 
indicator of poor outcome [3]. It has been among the 
most widely studied biomarkers in EC since it was first 
introduced in the eighties [4–7], and is of particular interest 
since it can be measured preoperatively and hence used to 
guide treatment decisions [8–10]. Ploidy status estimated by 
cytometric methods [11] has added prognostic information 
in several retrospective studies of EC, but has never been 
fully implemented in clinical treatment algorithms [12]. 
This is at least in part due to the lack of one common 
standardized method for measuring ploidy status in tumors 
[3]. In addition, its clinical usefulness as prognostic marker, 
adjusted for clinical and histopathologic variables, lacks 
validation in large prospective patient cohorts [13].
Aneuploidy is suggested to arise through a few 
major mechanisms, including mitotic checkpoint defects, 
centrosome over-duplication and defect sister chromatid 
cohesion [14], for instance by mutational loss of the cohesin 
subunit STAG2 [15]. However, the exact role of aneuploidy 
in tumor development and progression remains incompletely 
understood, and no single causative driver has been identified 
[16]. For EC, the prognostic impact of aneuploidy has been 
studied to a large extent, but associated transcriptional 
alterations have been much less explored. This is relevant 
for identifying shared molecular traits among aneuploid 
endometrial tumors, and hence to understand more about 
underlying biologic mechanisms in aggressive EC with 
possible relevance for new targeted therapies.
We therefore evaluated flow cytometry assessed 
DNA ploidy status in a large well-annotated EC 
patient cohort with long and complete follow-up, and 
demonstrated clear associations between aneuploidy 
and markers of poor outcome. Further, we examined 
transcriptional alterations reflecting ploidy status in 
primary EC lesions, revealing a prognostic ‘aneuploidy 
signature’ linked to low expression of chromosome 
15q genes, and shedding light on biologic mechanisms 
accompanying aneuploidy in EC.
RESULTS
Aneuploidy associates with markers for 
aggressive endometrial cancer
Of the 825 tumor samples with flow cytometry 
estimated ploidy status available, 638 were diploid (77%) 
and 187 aneuploid (23%). Example DNA histograms 
are shown in Supplementary Figure 1. Aneuploidy was 
significantly associated with well-established prognostic 
variables, including high age, FIGO stage and grade, 
non-endometrioid histology, and estrogen receptor and 
progesterone receptor (ER/PR) negativity (Table 1). The 
proportion of diploid and aneuploid tumors according to 
histologic subtype is shown in Figure 1. The frequency 
of aneuploid tumors was 38% among patients who later 
suffered recurrence and 42% in patients with metastasis at 
primary diagnosis, compared to 17% for patients without 
signs of systemic or recurrent disease (p<0.001).
Aneuploidy associates with reduced survival
In univariate survival analysis (Kaplan-Meier), 
the 5-year disease specific survival (DSS) for patients 
with diploid tumors was 89%, versus 68% for patients 
with aneuploid tumors (p<0.001, Figure 2A). Subgroup 
analyses confirmed aneuploidy as a significant marker 
for shorter survival in patients with FIGO stage 1 (Figure 
2B), as well as endometrioid and non-endometrioid tumors 
separately (Figure 2C and 2D). We also explored to what 
extent ploidy adds prognostic information to endometrioid 
and non-endometrioid subgroups with known ER/PR 
status. In non-endometrioid tumors with positive ER/
PR status (n=52), ploidy did not show any prognostic 
impact in univariate analysis (p=0.800, data not shown). 
However, ploidy significantly affected outcome in non-
endometrioid hormone receptor negative tumors (n=62), 
with 5-year DSS of 63% for patients with diploid versus 
35% for aneuploid tumors (p=0.010, Figure 2D).
Lymphadenectomy is advocated as staging 
procedure, and is documented to improve prognostication, 
however without effect on survival in randomized trials [17, 
18]. We therefore explored the prognostic impact of ploidy 
compared to ER/PR for three subgroups: patients with 
lymph node metastases, without lymph node metastases, 
and where lymphadenectomy was not performed. For 
patients with lymph node metastasis, ER/PR performed 
better than ploidy status (Supplementary Figure 2A and 
2B). In the other two groups, ER/PR status and ploidy 
added similar prognostic information in univariate survival 
analyses (Supplementary Figure 2C-2F).
In multivariate analysis, ploidy maintained 
independent prognostic impact on DSS, adjusting for 
the commonly applied standard prognostic markers: age, 
FIGO stage, histologic subtype and grade; with a hazard 
ratio (HR) of 1.62 for aneuploid tumors (95% confidence 
interval (CI) 1.11 – 2.37, p=0.013 (Supplementary Table 
1A). Due to a detected significant interaction between 
ER/PR and ploidy status (HR 3.03, 95% CI 1.23 – 
7.42, p=0.016), the two variables were not included 
simultaneously in the multivariate model. Replacing 
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ploidy with ER/PR status in the Cox model, a similar 
HR of 1.63 (95% CI 1.16 – 2.29, p=0.005) for ER/PR 
negativity was observed (Supplementary Table 1B). In 
subsequent Cox analyses stratified for ER/PR status, 
aneuploidy independently predicted poor outcome in the 
receptor negative group only, with HR 2.11 (95% CI 1.08 
– 4.15, p=0.029) (Table 2A and 2B).
Aneuploidy independently predicts lymph node 
metastasis and recurrence
Ploidy status was analyzed for its ability to predict 
lymph node metastasis and recurrence in binary logistic 
regression models adjusting for histologic subtype and 
grade. Due to the previously detected interaction, analyses 
were stratified for ER/PR status. In the group with ER/
PR negative status, aneuploidy independently predicted 
recurrence (n=96), with odds ratio (OR) 4.67 (95% CI 
1.78 – 12.27, p=0.002; Supplementary Table 2A), and 
lymph node metastasis (n=76) with OR 5.47 (95% CI 
1.58 – 18.99, p=0.007, Supplementary Table 2B). Thus, 
ploidy assessment may be a useful additional biomarker 
especially in ER/PR negative tumors, identifying high-
risk patients that could benefit from further systemic 
treatment.
Aneuploidy and its phenotype is reflected in a 
nine-gene ‘aneuploidy signature’
Significance analysis of microarray (SAM) was 
applied to assess aneuploidy related transcriptional 
alterations. Further, the machine learning algorithm support 
vector machine (SVM) was applied on the ranked SAM-list 
in order to identify the genes best discriminating between 
diploid and aneuploid samples. The nine top ranked genes 
from SAM were identified as the best discriminators. 
Of these, six were down- and three were upregulated 
(Supplementary Table 3). Unsupervised hierarchical 
clustering of the nine genes identified two patient clusters 
(Figure 3A). As expected, the ‘aneuploid cluster’ (n=46) 
reflected more aggressive clinical behavior, comprising 
the majority (83%) of flow cytometry aneuploid tumors, 
whereas the ‘diploid cluster’ (n=98) reflected less aggressive 
clinical features, dominated by flow cytometry diploid 
tumors (95%). Patients in the ‘aneuploid cluster’ had 
significantly worse survival than patients in the ‘diploid 
cluster’ (p=0.006, Figure 3B). An ‘aneuploidy score’ was 
calculated from expression values of the nine genes [19]. 
Similar to flow cytometry-assessed aneuploidy, a high 
score was significantly associated with all markers of 
aggressive disease (Supplementary Table 4), and reduced 
Table 1: Associations between clinicopathologic factors and DNA ploidy status by flow cytometry in 825 endometrial 
carcinomas
Diploid, n (%) Aneuploid, n (%) p-value*
Age, quartiles
 <58 178 (91) 18 (9) <0.001
 58 – 66 171 (83) 35 (17)
 66 – 75 145 (69) 66 (31)
 ≥ 75 144 (68) 68 (32)
Histologic type and gradea <0.001
 Endometrioid, grade 1-2 467 (87) 71 (13)
 Endometrioid, grade 3 75 (63) 44 (37)
 Non-endometrioid 76 (51) 72 (49)
FIGO stage <0.001
 Stage I 502 (81) 121 (19)
 Stage II 54 (74) 19 (26)
 Stage III 62 (66) 32 (34)
 Stage IV 20 (57) 15 (43)
ER/PR statusb <0.001
 ER and/or PR positive 389 (82) 84 (18)
 ER and PR negative 72 (61) 46 (39)
n=number of patients in each category; *: Pearson χ2-test; a: Data missing for 20 patients; b: Data missing for 234 patients
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survival (p<0.001, Figure 3C). Patients with flow cytometry 
aneuploid tumors had higher ‘aneuploidy scores’ than 
patients with flow cytometry diploid tumors (p<0.001, 
Supplementary Figure 3A). Interestingly, patients with 
flow-cytometry diploid/gene cluster aneuploid tumors had 
significantly higher ‘aneuploidy scores’ than patients with 
flow cytometry-assessed aneuploid/gene cluster diploid 
tumors (p<0.001, Supplementary Figure 3B). The score 
increased from premalignant through low grade malignant 
to high-grade malignant lesions. However, it did not increase 
further in metastatic lesions (Supplementary Figure 3C).
To further validate the link between the ‘aneuploidy 
score’, tumor aneuploidy and survival, the score was 
calculated from TCGA RNAseq data for 338 EC patients 
with ploidy status estimated by the ABSOLUTE algorithm 
[20]. We found a similar pattern for cluster formation 
based on the nine genes: patients segregated into two 
distinct clusters, one ‘aneuploid cluster’ including 41% of 
the tumors, associated with a more aggressive phenotype 
(high FIGO stage, p=0.04, high histologic grade and high 
stage, both p<0.001), and one ‘diploid cluster’ including 
tumors with less aggressive features. High ‘aneuploidy 
score’ also reflected reduced survival in this validation 
series (Supplementary Figure 4). The larger proportion of 
tumors in the TCGA ‘aneuploid cluster’ compared to our 
data set may reflect the TCGA strategy to enrich for more 
aggressive subtypes in the endometrial cancer series.
Since the proportion of aneuploid tumors differs 
significantly between histologic subtypes (Figure 1), we 
also explored the ‘aneuploidy signature’ in endometrioid 
and non-endometrioid tumors separately. The results 
for the endometrioid group were similar to those of the 
whole series, but more difficult to interpret in the non-
endometrioid group with small sample size (n=28) 
(Supplementary Figure 5A-5B).
Figure 2: Survival according to ploidy status. Kaplan-Meier curves showing DSS according to ploidy status, for all histologic 
subtypes A., FIGO stage 1 tumors B., endometrioid histologic type C. non-endometrioid histologic type D., and ER/PR negative non-
endometrioid histologic type E. For each category the number of cases is given, followed by number of deaths.
Figure 1: Ploidy status in histologic subtypes of endometrial cancer. Schematic overview of ploidy status (by flow cytometry) 
according to histologic subtype for 825 patients. n=number of patients in each category (percent).
Oncotarget9700www.impactjournals.com/oncotarget
Aneuploidy is related to low expression of genes 
on chromosome 15q
Interestingly, all six downregulated genes in the 
‘aneuploidy signature’ (i.e. low expression in aneuploid 
compared to diploid samples) were located on the q-arm 
of chromosome 15 (Figure 3D, Supplementary Table 3). 
To explore whether loss of 15q regions is a general feature 
of endometrial cancers, we assessed copy number data 
for endometrial cancer by the TCGA copy number portal 
[21, 22], without accounting for ploidy status. 79 peak 
regions of deletion were identified, of which three located 
to chromosome 15q. Two of these regions included four of 
the aneuploidy signature genes: C15orf57 and NDUFAF1 
in one peak region (residual q-value 3.44 x 10-5) 
and WVA9 and RPL4 in another peak region (residual 
q-value 0.0057). Further, we investigated the publicly 
accessible cBioportal for copy number alterations of 
the six genes in relation to mRNA expression level. 
For all six genes, a proportion of patients had deletion, 
with correspondingly lower mRNA expression levels 
compared to patients with normal gene copy number 
(Supplementary Figure 6). Gene Set Enrichment Analysis 
(GSEA) with MSigDB c1 positional gene sets, where 
each gene set corresponds to a cytoband on a human 
chromosome, showed that nine of the top 30 gene sets 
Table 2: Prognostic impact of ploidy status by flow cytometry adjusted for standard clinicopathologic variables, 
stratified for ER/PR expression (Cox regression model)





95% CI p-value Adjusted 
HR
95% CI p-value
Age 470 (100) 1.05 1.03 - 1.08 <0.001 1.04 1.02 - 1.07 0.001
Histologic type and grade <0.001 <0.001
Endometrioid grade 1-2 356 (76)
Endometrioid grade 3 62 (13) 4.57 2.41 - 8.66 2.81 1.44 - 5.47
Non-endometrioid 52 (11) 9.08 4.75 - 17.34 4.51 2.16 - 9.43
FIGO stage <0.001 <0.001
Stage I – II 409 (87)
Stage III – IV 61 (13) 11.53 6.80 - 19.56 8.97 5.12 - 15.70
Ploidy status 0.053 0.666
Diploid 386 (82)
Aneuploid 84 (18) 1.80 0.99 - 3.24 0.87 0.45 - 1.66





95% CI p-value Adjusted 
HR
95% CI p-value
Age 117 (100) 1.04 1.01 - 1.08 0.013 1.04 1.00 - 1.08 0.082
Histologic type and grade 0.009 0.184
Endometrioid grade 1-2 27 (23)
Endometrioid grade 3 28 (24) 0.87 0.27 - 2.85 1.02 0.31 - 3.41
Non-endometrioid 62 (53) 2.82 1.16 - 6.84 1.99 0.81 - 4.90
FIGO stage <0.001 <0.001
 Stage I – II 78 (67)
 Stage III – IV 39 (33) 6.66 3.39 - 13.07 5.56 2.77 - 11.13
Ploidy status 0.001 0.029
Diploid 71 (61)
Aneuploid 46 (39) 3.06 1.61 - 5.82 2.11 1.08 - 4.15
n=number of patients; HR: Hazard Ratio; CI: Confidence interval
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enriched in diploid tumors (FDR<25%), were located on 
chromosome 15q (Supplementary Table 5A). The same 
analysis was performed in subgroups of endometrioid 
and non-endometrioid tumors separately, with consistent 
results (Supplementary Figure 5C). These findings support 
the argument that aneuploidy is associated with reduced 
expression of genes on chromosome 15q, possibly due to 
deletion of chromosomal regions.
Integrated analyses of aneuploid tumors suggest 
the involvement of a variety of biological 
mechanisms and potential drug targets
GSEA identified gene sets related to a wide range of 
tumorigenic pathways and processes, including cell cycle 
regulation, cell proliferation and protein transcription 
as significantly enriched in aneuploid tumors. Notably, 
several gene sets related to glycolysis were enriched in 
aneuploid samples. Also, gene sets related to increased 
expression of known oncogenes including E2F, KRAS 
and MYC were frequently upregulated, as well as gene 
sets related to pluripotency, telomere maintenance and 
longevity (Supplementary Table 5B). These results 
suggest that a variety of biological mechanisms may 
be important in aneuploid tumors, further supported by 
connectivity map analysis. The 15 top-ranked compounds 
with negative enrichment score showed a large diversity of 
drugs potentially relevant for targeting aneuploid tumors 
(Supplementary Table 6).
Investigation of aneuploidy-related biomarker 
potential by STAG2 and PPP2R3A
Since mutational STAG2 inactivation may be 
involved in aneuploidy development [15], we investigated 
STAG2 protein expression by IHC as a potential marker 
for aneuploidy. No association was found between nuclear 
STAG2 expression and ploidy status, other prognostic 
markers except ER status, or survival (Supplementary 
Table 7, Supplementary Figure 7A-7C). Further, since 
PP2A complex alterations have been linked to whole 
genome doubling [21] and PPP2R3A expression was 
upregulated in the ‘aneuploidy signature’, we also 
evaluated PPP2R3A protein expression by IHC as a 
potential aneuploidy marker. No association between 
PPP2R3A expression and ploidy status, clinicopathologic 
variables or survival was observed (Supplementary Table 
7, Supplementary Figure 7D-7F).
DISCUSSION
Despite extensive support for ploidy as a 
prognostic factor in endometrial cancer [4-7, 23-
25], ploidy assessment is not implemented in routine 
clinical practice. The independent prognostic impact 
of aneuploidy, after adjusting for histopathologic 
parameters and surgical staging, is still uncertain, as 
all these parameters were often not included in earlier 
studies [4-7, 23-25]. Likewise, the prognostic impact 
Figure 3: ‘Aneuploidy signature’. Formation of diploid and aneuploid clusters based on the ‘aneuploidy signature’, related to flow 
cytometry ploidy status, FIGO stage, grade, histologic subtype, and ER/PR status. Unsupervised hierarchical clustering of 144 samples A. 
DSS for patients segregating within the ‘diploid’ compared to the ‘aneuploid cluster’ B., and for patients with low versus high ‘aneuploidy 
scores’ C. Schematic mapping of the six downregulated ‘aneuploidy signature’ genes, located on chromosome 15q D.
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of hormone receptor status in endometrial tumor tissue 
is well documented [26–28], and easily assessed by 
immunohistochemistry, however not applied in the 
routine diagnostic setting either. Nevertheless, the 
prognostic information derived from ploidy assessment 
has rarely been compared to hormone receptor status 
[29], a gap we have tried to fill. In multivariate survival 
models, ploidy status and ER/PR status contributed 
similar independent prognostic information based on 
adjusted hazard ratios. Interaction between ploidy 
status and ER/PR status was observed in multivariate 
survival and binary logistic regression analysis, and 
importantly, aneuploidy further improved the prediction 
of prognosis, lymph node metastasis and recurrence in 
tumors with loss of both receptors, all novel observations 
not previously reported. To our knowledge, interaction 
between ploidy status and hormone receptor status 
has never been reported before, and the biological 
underpinnings of this interesting phenomenon should 
be further explored in future studies. Also, in this large 
patient series with a substantial proportion subjected 
to staging lymphadenectomy, we demonstrated clear 
prognostic impact of ploidy status, especially in the 
group of patients where staging lymphadenectomy was 
not performed. These findings could have potential 
clinical impact, especially for identification of high-risk 
patients with need for further adjuvant therapy and closer 
follow-up.
There are likely numerous causes and consequences 
of aneuploidy [30]. We aimed to describe transcriptional 
traits characterizing aneuploid tumors to further explore 
mechanisms involved in aneuploidy development and/or 
maintenance in EC, and potentially reveal drugs of interest 
for further study. In this context, we are only aware of 
one differently designed study of 33 EC patients [31]. 
By GSEA, we identified gene sets related to cell cycle 
regulation, proliferation and transcription to be important 
in aneuploid tumors, similar to Habermann et al.’s findings 
using ingenuity pathway analysis. GSEA also identified 
gene sets related to a range of known oncogenes, including 
E2F, MYC and KRAS, as well as gene sets linked to cell 
longevity and pluripotency. This supports the argument 
that diverse pathways are dysregulated in aneuploid 
tumors. Connectivity Map analysis pointed towards a wide 
variety of drugs rather than one specific drug class, again 
supporting a complex biology underlying aneuploidy in 
EC, that might require diverse targeting approaches.
Previous attempts to characterize aneuploidy 
related transcriptional alterations in preclinical models 
have identified genes related to cellular stress response, 
response to reactive oxygen species and activated 
glycolysis as commonly upregulated in aneuploid cells 
[32, 33]. In line with this, gene sets related to glycolysis 
were identified as enriched in aneuploid tumors by GSEA. 
The upregulated ‘aneuploidy signature’ gene PGAM2 
(phosphoglycerate mutase 2), encodes a glycolytic enzyme 
whose activity increases in response to oxidative stress 
[34]. Increased PGAM2 level may indicate a link between 
oxidative stress, increased glycolysis and aneuploidy 
in EC, although this association needs to be further 
elucidated. Also, in a study of colorectal cancer [35], a 
cancer type sharing several molecular traits with EC [36–
38], copy number alterations with correlated expression 
changes (including 15q loss), affected the activity of the 
oxidative phosphorylation pathway [35]. Thus, a shift 
towards anaerobic glycolysis seems tentatively linked to 
aneuploidy across comparable tumor types. This should 
be further explored in particular for the development of 
new therapeutics.
PPP2R3A, encoding a subunit of the protein 
phosphatase 2A (PP2A) complex [39], was also 
upregulated in the ‘aneuploidy signature’, although we 
found no association between PPP2R3A expression level 
by IHC and ploidy status. PP2A complex subunits seem to 
be frequent targets in EC. PPP2R1A mutations often co-
occur with TP53 mutations, a marker for the serous-like 
subgroup with increased copy number, and are frequently 
seen in metastatic EC [40]. In addition, PPP2R1A and 
PPP2R2A alterations have been associated with whole 
genome doubling in a pan-cancer study of TCGA data 
[21]. Further studies are needed to understand the exact 
role of the PP2A complex in relation to aneuploidy, 
of particular interest since the PP2A complex might be 
targetable [39, 41].
Our ‘aneuploidy signature’ based on gene expression 
data seems to perform equally well as ploidy status 
estimation by flow cytometry for prediction of aggressive 
tumors, and its prognostic value was confirmed in an 
independent TCGA data set (n=338), also in the subgroup 
of endometrioid tumors. To our knowledge, this is the 
first study demonstrating a link between an aneuploidy 
related gene signature, clinicopathologic variables and 
survival in EC. The score was not associated with survival 
in subgroup analysis of the non-endometrioid cases, 
possibly because of the small group size, but potentially 
also due to more heterogeneous expression patterns in 
non-endometrioid tumors [36].
Further, the signature revealed an association 
between aneuploidy and low expression level of 
chromosome 15q genes, a finding that persisted in 
subgroup analysis of endometrioid and non-endometrioid 
tumors by GSEA. TCGA data supported that the 
observed low expression level of 15q signature genes 
could be related to altered gene dosage, i.e. deletion. In 
line with this, Habermann et al. identified 15q loss as a 
frequent phenomenon in aneuploid EC, both within the 
endometrioid (11% loss) and non-endometrioid (50% 
loss) subgroups [31]. Also, in the previously mentioned 
study by Sheffer et al, aneuploid colorectal tumors had 
a high frequency of 15q deletions and correspondingly 
low 15q gene expression level. Patients with 15q loss 
also had significantly reduced survival and higher disease 
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stage [35], in line with our findings. Whether this is an 
aneuploidy associated feature across different tumor types 
remains to be investigated.
In summary, we have shown that aneuploidy 
is associated with markers of aggressive endometrial 
cancer. Aneuploidy independently predicts poor survival 
adjusted for the commonly applied standard prognostic 
variables, and identifies patients with high risk of 
recurrence, lymph node metastasis and poor survival in 
hormone receptor negative tumors. Thus, aneuploidy 
should be further explored as a marker to identify patients 
who could potentially benefit from more aggressive 
surgical and adjuvant treatment. Aneuploidy associated 
transcriptional changes point to a complex underlying 
biological background, and reflects therapeutic challenges 
in targeting aneuploidy. However, a link towards increased 
glycolysis in aneuploid tumors is observed, and should be 
further explored. Our suggested ‘aneuploidy’ signature, 
linking aneuploidy with low expression of chromosome 
15q genes, equally identifies patients with aggressive 
disease and poor survival, and could provide an alternative 
method for ploidy status estimation in future diagnostics.
MATERIALS AND METHODS
Patient series and tumor samples
The patient population consisted of 1621 women 
treated for EC at Haukeland University Hospital, 
Norway, between 1981 and 2015, thoroughly described 
previously [42]. Approximately half of the patients had 
flow cytometry assessed ploidy status available, and 
were included for further analyses (n=825). Data from 
363 patients have been published previously [7]. For a 
subset of the patients, fresh frozen tissue (n=144) and 
tissue microarrays (TMA, n=526) were available for 
biomarker studies. Fresh frozen tissue was also available 
for 30 primary tumors, 18 complex atypical hyperplasias 
and 42 metastatic lesions without estimated ploidy status 
[27], used for extended evaluation of our ‘aneuploidy 
signature’. Estrogen and progesterone receptor (ER/PR) 
data was available for 1038 patients, 591 with overlapping 
ploidy status. Clinicopathologic and follow-up data were 
collected by review of the medical records, and if needed 
by additional correspondence with the primary physicians 
and referring hospitals. 92% underwent primary 
surgical treatment (at least hysterectomy with bilateral 
salpingo-oophorectomy; HBSO). Details regarding 
lymphadenectomy routines at different time periods 
have been described previously [42]. Disease stage was 
classified according to the FIGO 2009 criteria [43]; cases 
included prior to 2009 were reclassified. If HBSO was 
contraindicated, staging was based on curettage results, 
clinical examination, and preoperative imaging. Follow-
up time was defined as the interval between the date of 
primary treatment and the date of last follow-up/death. 
Median follow-up time of survivors was 5.02 years (range 
0.04 to 23.2); last follow-up was September 1st, 2015. The 
local Institutional Review Board approved the study (IRB-
number 2009-2315).
DNA ploidy analysis
Fresh tissue for DNA ploidy analysis was collected 
during surgery from an area judged macroscopically 
representative for the tumor. If HBSO was not performed, 
ploidy analyses were performed on tissue obtained from 
palliative surgery (n=7), or curettage (n=6). Tumor 
tissue was rinsed in phosphate-buffered saline, followed 
by ethanol fixation. DNA ploidy was analyzed by flow-
cytometry, according to previously described protocols 
[4, 7]. In selected analyses, tetraploid (n=8) and triploid 
tumors (n=1) were classified together with the aneuploid 
tumors, as numbers were too low for separate analyses. 
These nine tumors did not have microarray data and 
are therefore not included when determining the 9-gene 
signature described in subsequent sections.
Expression microarray and data analysis
RNA extracted from fresh frozen tumor tissue was 
hybridized to Agilent Whole Human Genome Microarray 
Kit, 44k (catalogue number G4 112F), according to the 
manufacturers instruction (www.agilent.com) and as 
described previously [28, 44]. Arrays were scanned 
using the Agilent Microarray Scanner Bundle. The 
software J-express (www.molmine.com) [45] was used 
for microarray analyses. Median spot intensity was used 
to define the intensity signal, and expression data were 
quantile normalized and log2-transformed. To identify 
differentially expressed genes between two groups, 
significance analysis of microarray (SAM) [46] was 
performed. For unsupervised hierarchical clustering we 
used additionally mean scaled expression values, with 
complete linkage and Pearson correlation as similarity 
measures.
Aneuploidy signature: To identify the minimal 
set of genes providing the highest discriminatory power 
between diploid (n=113, 78%) and aneuploid (n=31, 22%) 
samples, the machine learning method support vector 
machine (SVM), with 10-fold cross validation, was used 
on the ranked SAM-list. The method was implemented in 
R, using the Classification for Microarray package [47]. 
The genes discriminating between diploid and aneuploid 
samples with highest accuracy (n=9) were selected. From 
these genes, a gene signature score was calculated from 
mean and variance scaled expression values, subtracting 
the sum of expression values of downregulated genes 
from the sum of expression values of upregulated genes 
(in aneuploid compared to diploid samples) [19]. Upper 
quartile was used as cut-off to separate high and low 
scores in two groups. One of the identified signature 
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genes; THC252764 (Agilent probe A_24_P9140887, 
RPL4-variant Q59GY2) was not present in the TCGA 
validation dataset. Since the probe also targets the RPL4 
gene, data for RPL4 was included in the validation of the 
signature.
Connectivity map: A connectivity map analysis 
(www.broadinstitute.org/cmap/) [48] was performed to 
identify compounds generating signatures anti-correlated 
to the gene list separating aneuploid from diploid tumors. 
The input signature (SAM, FDR=0 and fold change ±1.5 
as cut-off) consisted of 287 differentially expressed genes 
(204 up- and 83 down-regulated).
GSEA: Gene set enrichment analysis (GSEA) 
(www.broadinstitute.org/gsea) [49], was performed using 
the Molecular Signatures Database (MSigDB version 
5.0, www.broadinstitute.org/gsea/msigdb) datasets 
c1 (positional gene sets), c2 (curated gene sets), c6 
(oncogenic gene sets) and Hallmark gene sets.
Analyses of the cancer genome atlas (TCGA) 
data
TCGA endometrial cancer level 3 data for 
mRNA expression estimated by RNAseq (IlluminaGA_
RNAseqV2, downloaded November 20th 2014), and 
clinical data (downloaded November 3rd 2014, https://tcga-
data.nci.nih.gov/tcga) were used for external validation. 
The ABSOLUTE algorithm was applied to estimate ploidy 
status for TCGA samples [20]. Cut-off value for diploid 
tumors was set to 2±0.05; samples with values outside 
this interval were considered aneuploid. The cBioPortal 
for cancer genomics [50, 51] and the copy number portal 
TCGA Tumorscape [21, 22] were applied to assess 
copy number status for 539 TCGA EC samples without 
accounting for ploidy status.
Immunohistochemistry (IHC)
The staining procedure and evaluation for ER and 
PR on tissue microarrays (TMA) has been described 
previously [26, 27, 52]. The TMA method has also 
been described and validated previously [53, 54]. ER 
and PR status were dichotomized in two categories for 
binomial analyses: positive ER and/or PR status versus 
negative ER and PR status by IHC staining. IHC of 
candidate aneuploidy markers STAG2 and PPP2R3A 
was performed on TMAs for a subset of 526 and 281 
patients, respectively. TMAs were sectioned (5 μm) for 
immunohistochemical staining: After 20 minutes boiling 
at pH 9 and peroxidase blocking (S2001 Dako, Denmark), 
slides were incubated for 60 minutes with STAG2 mouse 
monoclonal antibody SA-2 (J-12): sc-81852 (Santa Cruz 
Biotechnology, USA) at 1:500 dilution, or PPP2R3A 
rabbit polyclonal antibody HPA035829 (Sigma-Aldrich, 
USA), at 1:100 dilution. Secondary antibody EnVision 
mouse (labelled polymer-HRP anti-mouse, K4007 
Dako, Denmark) was applied for STAG2, and EnVision 
rabbit (labelled polymer-HRP anti-rabbit, K4003 Dako, 
Denmark) for PPP2R3A. Dab+Substrate Chromogen 
System (K3468 Dako, Denmark) was added, and slides 
counter-stained with hematoxylin. Staining index (SI) was 
calculated as the product of the area of staining, graded 
from 0-3, and the intensity of the staining, graded from 
0-3, as previously described [55, 56]. For STAG2, nuclear 
staining was registered, and lower quartile (SI 0-1) defined 
as low expression. For PPP2R3A, cytoplasmic staining 
was registered, and upper quartile (SI 6-9) defined as high 
expression.
Statistical analyses
Statistical analyses were performed using SPSS 
(Statistical Package of Social Sciences), version 23.0 (IBM 
SPSS Statistics, Armonk, NY, USA: IBM Corp, 2015). 
Associations between categorical variables were assessed 
by Pearson Chi-square test (Fisher’s exact test when 
appropriate). To compare the distribution of a continuous 
variable between two or more groups, Mann-Whitney 
U-test and Kruskal-Wallis test were applied, respectively. 
Univariate survival analyses were performed by the Kaplan-
Meier method, assessing survival differences between 
groups by the two-sided log-rank test (Mantel-Cox). 
To determine the optimal cut-off levels for high and low 
‘aneuploidy scores’, STAG2 expression level and PPP2R3A 
expression level, the Kaplan-Meier curves for the variables 
ranked by tertiles, quartiles and quintiles were examined 
visually, and the categories showing largest survival 
differences were chosen. For multivariate survival analyses, 
the Cox Proportional Hazards Regression Model was used, 
after visual assessment of included variables by a log-minus-
log plot to check the proportional hazards assumption. For 
the survival analyses, disease specific survival (DSS) was 
defined as primary endpoint, except in TCGA data, where 
overall survival (OS) was used. Binary logistic regression 
analysis was performed for prediction of recurrence and 
lymph node metastasis. A p-value below 0.05 was set as 
threshold significance level for all the statistical analyses.
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